STOCK TITAN
  1. Home
  2. News
  3. CTXR

Citius Pharmaceuticals Inc - CTXR STOCK NEWS

Welcome to our dedicated news page for Citius Pharmaceuticals (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Citius Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Citius Pharmaceuticals's position in the market.

News
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) completes Mino-Lok® Pivotal Phase 3 trial enrollment, with topline data expected in 2Q 2024. LYMPHIR™ BLA resubmission on track for early 2024. The company reports fiscal full year 2023 business and financial results, highlighting progress in pipeline development, clinical trials, and merger activities. Financially, the company has $26.5 million in cash and cash equivalents, with R&D and G&A expenses detailed for the full year 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.87%
Tags
earnings
-
News
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference on November 15, 2023
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) to Present at Sidoti Micro-Cap Virtual Conference on November 15, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
conferences
-
News
Citius Pharmaceuticals Announces Publication in Frontiers of Immunology of Positive Results from Solid Tumor Study of LYMPHIR™ in Combination with Checkpoint Inhibitor
Rhea-AI Summary
Citius Pharmaceuticals announces positive results from a preclinical study on LYMPHIR, showing that it enhances anti-tumor activity and improves overall survival when combined with anti-PD-1 treatment. Two Phase 1 trials are currently underway based on the study's findings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
none
News
Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.
Rhea-AI Summary
Citius Pharmaceuticals, Inc. and TenX Keane Acquisition have entered into a definitive agreement for a proposed merger. Citius Pharma will receive $675 million in equity of Citius Oncology and retain majority control. The merger is expected to close in the first half of 2024. Citius Oncology will focus on developing and commercializing novel targeted oncology therapies, with LYMPHIR as its flagship product. The transaction will provide Citius Oncology with improved access to the public equity markets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.36%
Tags
acquisition
-
News
Citius Pharmaceuticals Reschedules Participation in Sidoti Small-Cap Virtual Investor Conference for November 2023
Rhea-AI Summary
Citius Pharmaceuticals reschedules participation in Sidoti's Small-Cap Virtual Conference to November 2023 due to funeral services for late board member Howard Safir.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.72%
Tags
none
-
News
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
Rhea-AI Summary
Citius Pharmaceuticals mourns the loss of longtime board member Howard Safir
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.11%
Tags
management
News
Citius Pharmaceuticals, Inc. Receives Regulatory Guidance from the U.S. Food and Drug Administration (FDA) regarding the Planned Resubmission of the BLA for LYMPHIR™
Rhea-AI Summary
Citius Pharmaceuticals plans to resubmit Biologics License Application (BLA) for LYMPHIR™ in early 2024 after receiving guidance from FDA. No additional clinical trials requested. CRL remediation activities to be completed by end of the year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
none
-
News
Citius Pharmaceuticals to Participate in H.C. Wainwright and Sidoti Investor Conferences in September 2023
Rhea-AI Summary
Citius Pharmaceuticals, Inc. to present at investor conferences in September 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.1%
Tags
conferences
-
News
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) reported $33.3 million in cash and cash equivalents as of June 30, 2023, with a runway through August 2024. The company achieved 92 required events for the completion of the Mino-Lok® Phase 3 trial and is engaging with the FDA to address enhanced product testing requirements for LYMPHIR™. Citius also raised $15 million through a registered direct offering of common stock and warrants. The company's net loss was $8.5 million for the three months ended June 30, 2023, compared to a net loss of $8.9 million for the same period in 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.72%
Tags
earnings
News
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
Rhea-AI Summary
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) has achieved an important milestone in the clinical trial for Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. The Phase 3 pivotal superiority trial aims to determine the efficacy and safety of Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium. The primary endpoint is the time to a catheter failure event between randomization and TOC (Week 6) in the Intent-to-Treat (ITT) Population.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.14%
Tags
clinical trial
Stock CTXR logo
Citius Pharmaceuticals Inc

Nasdaq:CTXR

CTXR Rankings

#4060 Ranked by Market Cap
#3945 Ranked by Stock Gains
N/A Ranked by Dividends

CTXR Stock Data

125.34M
146.77M
7.74%
17.01%
7.81%
Medicinal and Botanical Manufacturing
Manufacturing
Link
US
Cranford

About CTXR

citius pharmaceuticals, inc., a specialty pharmaceutical company, develops and commercializes critical care products. it primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. the company is developing mino-lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in phase iii clinical trials; mino-wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; halo-lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and novecite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. citius pharmaceuticals, inc. was founded in 2007 and is headquartered in cranford, new jersey.